Breaking News

Samsung BioLogics Signs CMO Contract

Deal valued at $105 million

Related CONTENT

02.06.18

Samsung BioLogics has signed a CMO contract with an Asian pharmaceutical company. This contract is in addition to an already existing manufacturing contract. The approximate value of the contract will be $105 million for one year in 2018. The company said other terms of the agreement related to company's name, product, and production factory will not be disclosed.

Related Searches

Suggested For You

Samsung Biologics

Samsung Biologics

Samsung Biologics to Participate in Frontier 1.5D Initiative

Samsung Biologics to Participate in Frontier 1.5D Initiative

Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond

Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond

Samsung Biologics Signs Agreement with Kahr Medical

Samsung Biologics Signs Agreement with Kahr Medical

Samsung Biologics Expands Vaccine Manufacturing Capabilities

Samsung Biologics Expands Vaccine Manufacturing Capabilities

Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration

Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration

Samsung Bioepis Opens New Headquarters

Samsung Bioepis Opens New Headquarters

Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience

Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience

Samsung Biologics Names John Rim as President and CEO

Samsung Biologics Names John Rim as President and CEO

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Samsung Biologics Launches Virtual Showroom

Samsung Biologics Launches Virtual Showroom

Samsung Biologics Breaks Ground on

Samsung Biologics Breaks Ground on 'Super Plant'

Samsung Biologics Partners with Eli Lilly

Samsung Biologics Partners with Eli Lilly

Dow Development Laboratories

Dow Development Laboratories

Related Buyers Guide Companies

Samsung Biologics

...
Yeyoung Kim, Global PR Specialist 12.02.21
Breaking News | Industry News

Samsung Biologics to Participate in Frontier 1.5D Initiative

Will develop a climate risk management model as part of 2050 Carbon Neutral Strategy in response to the challenges associated with climate change.
09.14.21
Analytical Services | Bioanalytical Services

Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond

Build resiliency into analytical methods through careful consideration of chromatography partners.
Hazel Dickson, PhD, Marketing Manager, Chemistry Group, Waters Corporation 09.09.21
Bio News | Breaking News | Collaborations & Alliances | Industry News

Samsung Biologics Signs Agreement with Kahr Medical

Will support Kahr’s drug candidate DSP502, a TIGITxPD1 fusion protein.
Charles Sternberg, Assistant Editor 06.03.21
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Parenterals

Samsung Biologics Expands Vaccine Manufacturing Capabilities

To add mRNA vaccine drug substance manufacturing suite to expand portfolio of services.
Tim Wright, Editor, Contract Pharma 06.01.21